Baird R W upgraded shares of Alumis (NASDAQ:ALMS - Free Report) to a strong-buy rating in a research note published on Thursday, Zacks.com reports.
ALMS has been the subject of several other reports. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a report on Monday, August 19th. Morgan Stanley assumed coverage on Alumis in a research note on Tuesday, July 23rd. They issued an "overweight" rating and a $36.00 target price on the stock. Robert W. Baird started coverage on Alumis in a research note on Thursday. They set an "outperform" rating and a $25.00 price objective on the stock. Guggenheim initiated coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued a "buy" rating and a $32.00 target price for the company. Finally, HC Wainwright began coverage on shares of Alumis in a research note on Thursday, October 17th. They set a "buy" rating and a $30.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $27.50.
View Our Latest Stock Analysis on ALMS
Alumis Price Performance
ALMS stock remained flat at $11.32 on Thursday. The company had a trading volume of 39,371 shares, compared to its average volume of 158,308. Alumis has a 52-week low of $9.54 and a 52-week high of $13.53. The stock has a fifty day moving average price of $11.51.
Alumis (NASDAQ:ALMS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($23.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($21.53). On average, equities research analysts anticipate that Alumis will post -8 earnings per share for the current year.
Hedge Funds Weigh In On Alumis
A number of large investors have recently bought and sold shares of ALMS. Maven Securities LTD purchased a new stake in shares of Alumis during the 2nd quarter worth about $332,000. Millennium Management LLC acquired a new stake in shares of Alumis in the second quarter worth $3,376,000. Yu Fan purchased a new position in shares of Alumis in the 2nd quarter valued at $10,502,000. Ally Bridge Group NY LLC acquired a new position in shares of Alumis during the 2nd quarter valued at $8,229,000. Finally, SR One Capital Management LP acquired a new stake in Alumis in the 2nd quarter valued at $26,067,000.
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
